Variant Synonymizer: Platform to identify mutations defined in different ways is available now!

VarSy

Over 2,000 gene–disease validation summaries are now available—no login required!

Browse Summaries

SKP1 and Breast Cancer

The association between SKP1 (HGNC:10899) and breast cancer (MONDO_0007254) is supported by exploratory studies that have evaluated the role of circadian rhythm genes in breast cancer cohorts. In one study of 60 women with breast cancer, analysis of circadian gene variants—including SKP1—revealed nominal associations with sleep quality, although the findings did not meet robust multiple‐comparison thresholds (PMID:31303884). A second study employing weighted gene co-expression network analysis (WGCNA) on publicly available gene expression data identified SKP1 as a candidate hub gene in breast cancer, further suggesting its potential contribution to tumor biology (PMID:32764968). As the evidence is based on limited case numbers and primarily on exploratory transcriptomic analyses, the overall clinical validity is categorized as Limited, with minimal segregation data available.

Functional studies have well established that SKP1 plays an essential role as part of the SCF (Skp1-Cullin-F-box) ubiquitin ligase complex, critical for cell cycle regulation and proteolysis, which are processes relevant to cancer pathogenesis. However, direct functional experiments linking SKP1 disruption specifically to breast cancer development are sparse (PMID:10514433). In conclusion, while genetic and functional data implicate SKP1 in cellular processes that could influence breast cancer severity, the current evidence remains exploratory. Key take‑home: Further rigorous studies are required to firmly establish the clinical utility of SKP1 as a biomarker or therapeutic target in breast cancer.

References

  • Journal of circadian rhythms • 2019 • Genetic Variants in Circadian Rhythm Genes and Self-Reported Sleep Quality in Women with Breast Cancer PMID:31303884
  • OncoTargets and therapy • 2020 • Identification of Important Modules and Biomarkers in Breast Cancer Based on WGCNA PMID:32764968
  • The Journal of biological chemistry • 1999 • Molecular dissection of the interactions among IkappaBalpha, FWD1, and Skp1 required for ubiquitin-mediated proteolysis of IkappaBalpha PMID:10514433

Evidence Based Scoring (AI generated)

Gene–Disease Association

Limited

Evidence from two exploratory studies in breast cancer cohorts—one analyzing circadian gene variants in 60 women (PMID:31303884) and another using WGCNA (PMID:32764968)—supports a limited association with breast cancer.

Genetic Evidence

Limited

The genetic evidence is based on exploratory analyses with limited proband numbers and lacks robust family segregation or recurrent pathogenic SKP1 variants.

Functional Evidence

Limited

While SKP1’s role in the SCF ubiquitin ligase complex is well-documented, direct experimental evidence linking its dysfunction to breast cancer is not well-established (PMID:10514433).